Patents Filed

CLOSE ACCORDIAN
Covid Bioassay to Determine Severity and Therapy

A DNA-based test for COVID-19 susceptibility to severe infection presents an enticing investment opportunity with profound implications for both public health and financial returns. By analyzing an individual’s genetic profile through proprietary molecular testing we are able to identify those at higher risk of developing severe COVID-19 symptoms, enabling targeted, preemptive preventive measures and treatment strategies. This proprietary Assay will play a pivotal role in shaping the future of pandemic preparedness, public health response, and personalized medicine.

SYSTEMS AND METHODS FOR PROVIDING MEDICATION TREATMENTS BASED ON PHARMACOGENETIC TESTING

We have focused on the development and deployment of novel advanced diagnostic tools (e.g., qPCR based miRNA molecular testing to assess and monitor brain injuries resulting from trauma, such as concussions and PTSD. Traumatic Brain Injury (“TBI”) testing is of paramount importance due to its potential to revolutionize the way we detect and manage brain injuries, particularly in high-risk populations like athletes and military personnel. Accurate and early diagnosis can prevent long-term complications, including cognitive impairment, and can guide more tailored treatment plans.

Systems and Methods for Providing Medication Treatments Based on Pharmacogenetic Testing

Our Pharmacogenetics “PGx” Assay focuses on understanding how an individual’s genetic makeup influences their response to medications. Our PGx Assay represents a groundbreaking intersection of genetics and pharmaceuticals. Our cutting-edge customized PGx testing gene array-based testing platform will provide the ability to decipher over 850,000 genetic variants, including 34 Tier One Genes across over 1000 markers that show the highest level of PGx evidence, giving clinicians and patients the ability to identify and customize the correct medication tailored for their unique genetic profile. This testing will allow the ability to significantly enhance drug efficacy, reduce adverse reactions, and optimize treatment outcomes, thereby significantly improving treatment outcomes.